Innovation in interventional cardiology

reSept atrial septal defect occluder

Dr. José R. Rumoroso

02/11/2021

reSept occluder

The reSept atrial septal defect occluder (atHeart Medical, Switzerland) is the first occluder to have a bioresorbable structure with no metal components. The frame is made with bioabsorbable filaments that support two polyester patches with radiopaque markers. This frame resorbs over a period of 24 months, while the polyester patches and the radiopaque markers remain at the implantation site.

The device is implanted with a 12-French introducer sheath; currently 3 sizes are available, covering the closure of defects from 4 to 22 mm.

In August 2021, the first 5 patients were treated as part of the ASCENT-ASD clinical trial (NCT04591392) to demonstrate its safety and efficacy in the treatment of ostium secundum-type atrial septal defects compared with the clinical standards of other occluders.

The device is designed as a restorative therapy and is very promising, as it does not leave any metallic structures that could cause future problems.

Keywords: Atrial septal defects, bioresorbable ASD occluder.

Save
Cookies user prefences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Analytics
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.
Google Analytics
Accept
Decline